ARTICLE | Company News
OSE regains rights to FR104 from J&J
November 9, 2018 6:00 PM UTC
OSE Immunotherapeutics S.A. (Euronext:OSE) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) will return to OSE worldwide rights to FR104. The compound has completed a Phase I trial to treat rheumatoid arthritis; OSE said it is evaluating development options, including another partnership. FR104 is a pegylated monovalent antibody fragment antagonist of CD28 receptor...